Cannabis and Epilepsy

Not medical advice

This article is informational, not medical advice. Epilepsy is a serious neurological condition. Stopping or changing anti-seizure medication without supervision can trigger status epilepticus, which can be fatal. Do not start, stop, or substitute any treatment — including CBD — based on what you read here. Discuss options with a neurologist or epileptologist, ideally one familiar with cannabinoid pharmacology.

Plain-language summary

Cannabidiol (CBD), one of the major compounds in cannabis, reduces seizures in three rare, severe epilepsy syndromes: Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex (TSC). This is established by randomized controlled trials and is the basis for the FDA-approved drug Epidiolex (Epidyolex in Europe) ^[1][2][3][4].

For the much larger group of people with common adult epilepsies — focal epilepsy, generalized tonic-clonic seizures from other causes, drug-resistant epilepsy not in the above syndromes — the evidence is thinner. Open-label studies show some benefit, but randomized trials are limited Weak / limited.

THC-dominant cannabis is not an established epilepsy treatment. At high doses THC has shown both anticonvulsant and pro-convulsant effects in animal and human reports Disputed.

CBD is not benign: it raises liver enzymes in a meaningful fraction of patients, interacts with several anti-seizure drugs (notably clobazam and valproate), and causes sedation, diarrhea, and appetite loss ^[1][5].

What probably works

Pharmaceutical CBD (Epidiolex) for Dravet syndrome. In a randomized, double-blind, placebo-controlled trial, CBD at 20 mg/kg/day reduced convulsive seizures by a median of 39% versus 13% on placebo ^[1]. Strong evidence

Pharmaceutical CBD for Lennox-Gastaut syndrome (LGS). Two RCTs showed CBD reduced drop seizures by roughly 40-44% versus 17-22% on placebo ^[2][3]. Strong evidence

Pharmaceutical CBD for tuberous sclerosis complex. An RCT showed CBD reduced TSC-associated seizures significantly more than placebo, leading to FDA approval expansion in 2020 ^[4]. Strong evidence

The effect size is real but modest: most patients still have seizures. About 5% of trial patients became seizure-free. CBD works best as an add-on to existing anti-seizure medications, not as a replacement.

What might work

CBD for other drug-resistant epilepsies. Expanded access programs and open-label studies in adults and children with mixed refractory epilepsies have reported median seizure reductions around 36-50% ^[6]. These studies lack placebo controls, and open-label CBD studies in epilepsy historically show large placebo responses. Weak / limited

Artisanal / hemp-derived CBD oils. Some families report benefit, and the famous "Charlotte's Web" case helped drive research. But product testing repeatedly finds artisanal CBD products with inaccurate labels, contamination, or unexpected THC content ^[7]. Any benefit observed cannot be confidently attributed to the listed CBD dose. Weak / limited

CBD for status epilepticus or acute seizures. Limited case series and animal data. Not an established acute treatment. Weak / limited

What doesn't work or has weak evidence

THC-dominant cannabis for epilepsy. There is no good controlled human evidence that smoked or vaporized high-THC cannabis controls seizures. Animal studies are mixed; high THC doses can be pro-convulsant in some models, and synthetic cannabinoids (K2/Spice) are a documented seizure trigger in humans ^[8]. Disputed

The "1:1 CBD:THC ratio is best" claim. Popular in dispensary culture; not supported by RCT evidence for epilepsy. Anecdote

The "entourage effect" as a reason to prefer whole-plant extracts over isolated CBD for seizures. Plausible biologically and sometimes cited in observational data, but no head-to-head RCT has shown whole-plant CBD beats pharmaceutical CBD for any epilepsy syndrome ^[9]. Weak / limited

Specific terpenes (linalool, myrcene, etc.) as anticonvulsants in humans. Preclinical signals exist; human clinical evidence is essentially absent. No data

What we don't know

• Optimal CBD dose for non-Dravet/LGS/TSC epilepsies.
• Long-term safety of high-dose CBD (>10 years of daily use).
• Whether CBD's benefit in epilepsy comes from direct anticonvulsant action, from raising clobazam's active metabolite (N-desmethylclobazam) levels ^[5], or both. This matters because the interaction-driven part of the effect would not generalize to patients not on clobazam.
• Whether other cannabinoids (CBDV, CBDA, THCV) have meaningful anticonvulsant effects in humans. Preclinical work is promising; human trials are limited ^[10].
• Pediatric neurodevelopmental effects of chronic cannabinoid exposure.

Comparison with standard treatments

First-line epilepsy treatments are anti-seizure medications (ASMs) like levetiracetam, valproate, lamotrigine, carbamazepine, and many others. About two-thirds of people with epilepsy achieve good seizure control on ASMs. For the remaining one-third (drug-resistant epilepsy), options include further ASM trials, ketogenic diet, vagus nerve stimulation, responsive neurostimulation, and epilepsy surgery ^[11].

Pharmaceutical CBD's seizure-reduction effect size is comparable to a typical add-on ASM in refractory epilepsy. It is not more effective than surgery in surgical candidates, and it has not been compared head-to-head with the ketogenic diet in Dravet or LGS.

For a child with Dravet, LGS, or TSC who has failed multiple ASMs, pharmaceutical CBD is now a standard option recommended in guidelines ^[12]. For an adult with common focal epilepsy, it is not standard of care.

Risks and side effects

From RCT and post-marketing data on pharmaceutical CBD ^[1][2][5]:

• Liver enzyme elevations: ~13% of patients, more common when combined with valproate. Can require dose reduction or discontinuation.
• Sedation and somnolence: common, especially with clobazam (CBD inhibits CYP2C19, raising N-desmethylclobazam levels — the sedating metabolite).
• Diarrhea, decreased appetite, weight loss.
• Drug interactions: clinically significant with clobazam, valproate, warfarin, tacrolimus, everolimus, and others. CBD inhibits multiple cytochrome P450 enzymes.
• Withdrawal risk: abrupt discontinuation can trigger seizures.

For artisanal CBD products, add: unknown actual CBD content, possible THC contamination (problem in children and for drug testing), heavy metal and pesticide residues in poorly regulated products ^[7].

For THC-containing cannabis in people with epilepsy: acute intoxication, possible seizure threshold lowering at high doses, and concerns about adolescent brain development.

Sources

How this page was made